Microdosing Orforglipron (Foundayo): What Is Actually Known

Orforglipron is the first GLP-1 receptor agonist that is not a peptide. It is a small molecule, taken as a daily tablet, and unlike the oral semaglutide that came before it there is no fasting ritual attached — the label carries no food or water restriction at all, where oral semaglutide must be taken on an empty stomach with no more than four ounces of water and nothing else for at least 30 minutes ^9,8.

That single practical difference is why it matters to anyone thinking about a low dose. A tablet you can take with breakfast, in a strength printed on the box, is a fundamentally different proposition from drawing a fraction of a unit out of a compounded vial. So it is worth being precise about what is known, and this page is going to spend most of its length on what is not.

Two facts first, because both are routinely got wrong.

It is approved for weight management, not diabetes. The US approval — NDA 220934, granted 1 April 2026 — covers chronic weight management ⁷. There is a large, positive phase 3 diabetes program behind it ^3,6, and no US diabetes indication. Describing it as a diabetes drug in the United States is simply wrong.

The trial milligrams and the label milligrams are different numbers. The marketed tablet is a different formulation from the one studied, and the label maps the investigational 6, 12 and 36 mg doses to 5.5, 9 and 17.2 mg respectively ⁹. That is not a constant ratio, so it cannot be eyeballed. Any dose figure lifted out of a journal paper and printed next to the brand name is wrong unless it has been converted. This is the single most likely error you will encounter in coverage of this drug, including from people quoting the trials accurately.

What the dose-response actually looks like

The useful thing about orforglipron for a low-dose reader is that it has been studied across a wide dose range, in trials designed to look at exactly that.

In the pivotal obesity trial, 3,127 adults with obesity and without diabetes took 6, 12 or 36 mg or placebo for 72 weeks. Weight change was −7.5%, −8.4% and −11.2% against −2.1% on placebo ⁴. Read as placebo-adjusted effect, the lowest arm delivers roughly 59% of what the top arm delivers — for one sixth of the drug.

In the phase 3 early-diabetes trial, 559 adults took 3, 12 or 36 mg or placebo for 40 weeks. HbA1c fell 1.24, 1.47 and 1.48 points against 0.41 on placebo, while weight fell far less at the bottom of the range than the top ³. Those two numbers together are the most informative thing published about this drug: glycaemic effect saturates early and weight effect does not. At 3 mg you get around three quarters of the achievable HbA1c effect and under half of the achievable weight effect.

The phase 2 dose-ranging work points the same way, in both indications ^2,10, and the pattern holds in people with obesity and type 2 diabetes together ⁵.

If you are taking a GLP-1 for metabolic reasons rather than to lose a large amount of weight, that shape is genuinely relevant, and it is the strongest evidence-based argument for a lower dose that exists anywhere in this drug class. It is also not the same thing as a microdose, which is the next problem.

The two lowest strengths have no efficacy data at all

The marketed product starts at 0.8 mg once daily, then steps up at intervals of at least 30 days through 2.5 mg, 5.5 mg, and on to 9, 14.5 or 17.2 mg ⁹.

The lowest strength with any efficacy evidence behind it is 5.5 mg — the trials' 6 mg. The 0.8 mg and 2.5 mg tablets have no efficacy data whatsoever. They exist as mandatory titration steps to get you tolerably to a dose that was studied, not as doses in their own right.

That is a specific and important thing to understand if you are attracted to the idea of settling at the bottom of the ladder. The only published human exposure anywhere below the trials' 3 mg is a 92-person phase 1a study in healthy volunteers — single doses of 0.3 to 6 mg and four weeks of daily dosing to targets of 2 to 24 mg ¹. That study establishes pharmacokinetics and short-term safety in healthy people. It does not establish that anything happens at those doses in anyone who needs a result.

So "microdosing orforglipron" splits into two very different propositions:

• •Stopping escalation early, at 5.5 or 9 mg. This is a real, label-permitted strategy sitting on real trial data. The label explicitly allows the dose to be individualized, and 5.5 mg is a studied dose with a published effect size.
• •Settling at 0.8 or 2.5 mg. This is off the edge of the evidence. No trial has measured what those strengths do to weight or metabolic markers in anyone.

And a trial arm is not a maintenance strategy either. No study has ever tested escalating and then deliberately holding below the maximum, against a standard titration. The label permits stopping; nobody has measured what happens when you do. A 72-week trial arm at 6 mg tells you what 72 weeks at 6 mg does — it does not tell you what happens to someone who reaches 17.2 mg and steps back down, which is a different trajectory and a different question.

Tolerability is the usual argument, and it is thinner than it sounds

The standard case for a lower dose is that it is easier to live with, and the discontinuation figures point that way: withdrawal for adverse events ranged from 5.3% to 10.3% across the orforglipron arms of the pivotal obesity trial against 2.7% on placebo, rising with dose ⁴.

But that is not the comparison a low-dose reader actually needs. Nothing published compares tolerability at a matched degree of weight loss. Fewer side effects at a dose that also does less is not a free lunch; it is a smaller dose of everything. Whether a low dose is better tolerated per kilogram lost than a higher dose is untested, in this drug and in the class generally — the same gap we describe in low dose vs full dose.

What is not known, stated plainly

This section is the point of the page.

• •No body-composition, lean-mass, bone-density or bone-turnover data exists for orforglipron at any dose. Not less at low doses — none at all. If you are choosing a lower dose to protect muscle or bone, there is nothing here to base that on, and the broader class evidence is thinner than most people assume.
• •No published cardiovascular or renal outcome results. The evidence is weight and glycaemia, over 40 to 72 weeks.
• •Long-term data is thin. The pivotal obesity trial's registry record still carries an estimated completion in 2027 ¹¹; the early-diabetes trial completed in April 2025 ¹². The 72-week readouts are published; what happens over years is not.
• •No dose below the trials' 3 mg has been tested for effect in anyone who needs one.

None of that makes the drug a bad choice. It makes the confident low-dose claims being made about it unsupported, which is a different and more useful thing to know.

What this means for the compounded market

There is no compounded orforglipron and there should not be. It is a new molecular entity under patent with no generic pathway, so any product offered under that name from a compounding route is something you should treat with considerable suspicion. That is a different situation from semaglutide and tirzepatide, whose compounded supply arose from a shortage and whose legal footing has narrowed sharply since — which we track in is compounded microdose GLP-1 still legal.

What orforglipron does change is the practical calculus. The reason a lot of people microdose is that the alternative is expensive, and the drug they can afford comes in a vial they have to measure out of. A daily tablet with a printed strength and no fasting rule removes the measurement problem entirely, and the strengths at the bottom of its ladder are lower relative to the top than anything available in an injectable. If you are drawn to microdosing because splitting a vial makes you nervous, that is worth weighing — and it is worth weighing against price, which is where what the plan actually costs across a year matters more than the headline.

The honest summary

Orforglipron has the best-characterized dose-response curve of any GLP-1 available, and it genuinely shows that a substantial part of the effect arrives early — most of the glycaemic effect, and well under half of the weight effect. That is a real, published, checkable argument for not assuming the top dose is the target.

It is not an argument for the bottom of the ladder. The two lowest marketed strengths have no efficacy data behind them, nobody has tested holding below the maximum as a strategy, and there is no body-composition or bone data at any dose. Everything else being written about microdosing this drug is running ahead of that.